Cervical Dystonia Management Market : By Administration (Oral, Intravenous), By Drug Class (Dopaminergic drugs, Anti-cholinergic drugs, GABA Agonists, Anti Convulsants), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Others), and Geography   

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Cervical Dystonia Management Market size was valued at 114.1 million in 2021 and is expected to reach 160.6 million by 2028, at a CAGR of 5.0% during the forecast period 2022 to 2028. Cervical dystonia, also known as spasmodic torticollis, rare neurological disorder that originates in the brain. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect the quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood. The cause of cervical dystonia is unknown, although a genetic susceptibility is thought to underlie some cases. According to the Association of neurological American Surgeons about 250,000 people are having cervical dystonia every year. According to National organization for rare diseases (NORD) it is anticipated that around 60,000 individuals in US are suffering with cervical dystonia. Key Developments: InMarch, 2019, Ipsen Biopharmaceuticals Inc., the Canadian affiliate of Ipsen  has received Health Canada approval for DYSPORT THERAPEUTIC™ (abobotulinumtoxinA) to treat cervical dystonia. In 2019, Merz Pharmaceuticals received USFDA approval fo Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm.

Global Cervical Dystonia Management Market Summary

Study Period

2023-29

Base Year

2022

CAGR

5%

Largest Market

Asia-Pacific

Fastest Growing Market

North-America
Cervical Dystonia Management Market Dynamics

The major driving factors for the market for cervical dystonia market is increase in aging population across the globe. Females are more likely to be get affected by cervical dystonia. Besides this increase in treatment for cervical dystonia and improvement in infrastructure provided fuel for the growth of the market. Furthermore, low and increase in cost of treatment is the major cause for restraining the growth of cervical dystonia market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Cervical Dystonia Management Market Segmentation

Drug class
  • Dopaminergic drugs
  • Anti-cholinergic drugs
  • GABA Agonists
  • Anti Convulsants
Route Administration
  • Oral
  • Intravenous
Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Others

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

1. Executive Summary 2. Global Cervical Dystonia Management Market Introduction 2.1. Global Cervical Dystonia Management Market – Taxonomy 2.2. Global Cervical Dystonia Management Market –Definitions 2.2.1. Route of Administration 2.2.2. Drug Class 2.2.3. Distribution Channel 3. Global Cervical Dystonia Management Market Dynamics 3.1. Drivers 3.2. Restraints 3.3. Opportunities/Unmet Needs of the Market 3.4. Trends 3.5. Global Cervical Dystonia Management Market Dynamic Factors - Impact Analysis 3.6. Global Cervical Dystonia Management Market – Regulations 3.6.1. U.S. 3.6.2. Europe 3.7. Global Cervical Dystonia Management Market –Trends 4. Global Cervical Dystonia Management Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 4.3. Market Opportunity Analysis 5. Global Cervical Dystonia Management Market, By Route of Administration, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1. Oral 5.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.1.3. Market Opportunity Analysis 5.2. Intravenous 5.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 5.2.3. Market Opportunity Analysis 6. Global Cervical Dystonia Management Market Forecast, By Drug Class, 2013 - 2017 and Forecast, 2018 – 2024 6.1. Dopaminergic drugs 6.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.1.3. Market Opportunity Analysis 6.2. Anti-cholinergic drugs 6.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.2.3. Market Opportunity Analysis 6.3. GABA Agonists 6.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.3.3. Market Opportunity Analysis 6.4. Anti Convulsants 6.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 6.4.3. Market Opportunity Analysis 7. Global Cervical Dystonia Management Market Forecast, By End User, 2013 - 2017 and Forecast, 2018 – 2024 7.1. Hospital Pharmacies 7.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.1.3. Market Opportunity Analysis 7.2. Retail Pharmacies 7.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.2.3. Market Opportunity Analysis 7.3. Others 7.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 7.3.3. Market Opportunity Analysis 8. Global Cervical Dystonia Management Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.1. North America 8.1.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.1.3. Market Opportunity Analysis 8.2. Europe 8.2.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.2.3. Market Opportunity Analysis 8.3. Asia-Pacific 8.3.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.3.3. Market Opportunity Analysis 8.4. Latin America 8.4.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.4.3. Market Opportunity Analysis 8.5. Middle East and Africa 8.5.1. Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 8.5.3. Market Opportunity Analysis 8.6. Global Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Region, 2018 – 2024 9. North America Cervical Dystonia Management Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 9.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 9.1.1. Oral 9.1.2. Intravenous 9.2. Drug Class Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.2.1. Dopaminergic drugs 9.2.2. Anti-cholinergic drugs 9.2.3. GABA Agonists 9.2.4. Anti Convulsants 9.3. End User Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 9.3.1. Hospital pharmacies 9.3.2. Retail pharmacies 9.3.3. Others 9.4. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 9.4.1. U.S. 9.4.2. Canada 9.5. North America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2018 – 2024 9.6. North America Cervical Dystonia Management Market Dynamics – Trends 10. Europe Cervical Dystonia Management Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 10.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 10.1.1. Oral 10.1.2. Intravenous 10.2. Drug Class Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.2.1. Dopaminergic drugs 10.2.2. Anti-cholinergic drugs 10.2.3. GABA Agonists 10.2.4. Anti Convulsants 10.3. End User Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 10.3.1. Hospital pharmacies 10.3.2. Retail pharmacies 10.3.3. Others 10.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 10.4.1. Germany 10.4.2. UK 10.4.3. France 10.4.4. Spain 10.4.5. Italy 10.4.6. Russia 10.4.7. Poland 10.4.8. Rest of Europe 10.5. Europe Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2018 – 2024 10.6. Europe Cervical Dystonia Management Market Dynamics – Trends 11. Asia-Pacific Cervical Dystonia Management Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 11.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 11.1.1. Oral 11.1.2. Intravenous 11.2. Drug Class Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.2.1. Dopaminergic drugs 11.2.2. Anti-cholinergic drugs 11.2.3. GABA Agonists 11.2.4. Anti Convulsants 11.3. End User Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 11.3.1. Hospital pharmacies 11.3.2. Retail pharmacies 11.3.3. Others 11.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 11.4.1. Japan 11.4.2. China 11.4.3. India 11.4.4. ASEAN 11.4.5. Australia & New Zealand 11.4.6. Rest of Asia-Pacific 11.5. Asia-Pacific Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2018 – 2024 11.6. Asia-Pacific Cervical Dystonia Management Market Dynamics – Trends 12. Latin America Cervical Dystonia Management Market Analysis, 2012 - 2012 - 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 12.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 12.1.1. Oral 12.1.2. Intravenous 12.2. Drug Class Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.2.1. Dopaminergic drugs 12.2.2. Anti-cholinergic drugs 12.2.3. GABA Agonists 12.2.4. Anti Convulsants 12.3. End User Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 12.3.1. Hospital pharmacies 12.3.2. Retail pharmacies 12.3.3. Others 12.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 12.4.1. Brazil 12.4.2. Mexico 12.4.3. Argentina 12.4.4. Venezuela 12.4.5. Rest of Latin America 12.5. Latin America Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2018 – 2024 12.6. Latin America Cervical Dystonia Management Market Dynamics – Trends 13. Middle East and Africa Cervical Dystonia Management Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn) 13.1. Route of Administration Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) 13.1.1. Oral 13.1.2. Intravenous 13.2. Drug Class Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.2.1. Dopaminergic drugs 13.2.2. Anti-cholinergic drugs 13.2.3. GABA Agonists 13.2.4. Anti Convulsants 13.3. End User Type Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) 13.3.1. Hospital pharmacies 13.3.2. Retail pharmacies 13.3.3. Others 13.4. Country Analysis 2013 - 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) 13.4.1. Gulf Cooperation Council (GCC) Countries 13.4.2. Israel 13.4.3. South Africa 13.4.4. Rest of MEA 13.5. MEA Cervical Dystonia Management Market - Opportunity Analysis Index, By Route of Administration, By Drug Class, By End Use and Country, 2018 – 2024 13.6. MEA Cervical Dystonia Management Market Dynamics – Trends 14. Competition Landscape 14.1. Strategic Dashboard of Top Market Players 14.2. Company Profiles (Introduction, Financial Analysis, Route of Administration & Service Offerings, Key Developments, Strategies, and SWOT Analysis) 14.2.1. Ashland Inc.(U.S.) 14.2.2. AkzoNobel (Netherlands) 14.2.3. The DOW Chemical Company (U.S.) 14.2.4. Archer Daniels Midland Company(U.S.) 14.2.5. Associated British Foods PLC (UK) 14.2.6. Colorcon, Inc.(U.S.) 14.2.7. BASF SE(Germany) 14.2.8. Evonik Industries AG (Germany) 14.2.9. Innophos Holdings Inc. (U.S.) 14.2.10. J.M. Huber Corporation (U.S.) 14.2.11. FMC Corporation (U.S.) 14.2.12. Roquette Group (France) 14.2.13. Croda International PLC (UK) 14.2.14. Merck KGaA (Germany) 14.2.15. Lubrizol Corporation (U.S.) 15. Research Methodology 16. Key Assumptions and Acronyms
  • Ashland Inc.(U.S.)
  • AkzoNobel (Netherlands)
  • The DOW Chemical Company (U.S.)
  • Archer Daniels Midland Company(U.S.)
  • Associated British Foods PLC (UK)
  • Colorcon, Inc.(U.S.)
  • BASF SE(Germany)
  • Evonik Industries AG (Germany)
  • Innophos Holdings Inc. (U.S.)
  • J.M. Huber Corporation (U.S.)
  • FMC Corporation (U.S.)
  • Roquette Group (France)
  • Croda International PLC (UK)
  • Merck KGaA (Germany)
  • Lubrizol Corporation (U.S.)